Asseman P, Bauchart J J, Amrouni N, Lesenne M, Neuville C, Loubeyre C, Elkohen M, Thery C, Jude B
Hôpital Cardiologique, Lille.
Ann Cardiol Angeiol (Paris). 1992 Mar;41(3):163-9.
Non-valvular atrial fibrillation multiplies the risk of presumed embolic events by a factor of four. The hemorrhagic risk of anticoagulant treatment varies considerably and its prophylactic efficacy was not tested in any randomised trial before the end of 1989. The recommendations of experts at that time recognised that data were inadequate. The publication since of four randomised trials involving 3,049 patients has provided a more objective base for management decisions, highly in favour of the anticoagulation of cases of non-isolated atrial fibrillation in the absence of contraindications.
非瓣膜性心房颤动会使假定的栓塞事件风险增加四倍。抗凝治疗的出血风险差异很大，并且在1989年底之前没有任何随机试验对其预防效果进行过测试。当时专家的建议认识到数据并不充分。此后发表的四项涉及3049名患者的随机试验为管理决策提供了更客观的依据，强烈支持在无禁忌症的情况下对非孤立性心房颤动患者进行抗凝治疗。
